ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
JPJavier PascualGAGerhardt AttardFBFrançois‐Clément BidardGCGiuseppe CuriglianoLDLeticia De Mattos‐Arruda
Instituto de Investigación Biomédica de Málaga · University College London · +32 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
645
total citations
- FWCI
- 53.83
- Percentile
- 100%
- References
- 166
Citations per year
Authors
20- JPJavier Pascual
Instituto de Investigación Biomédica de Málaga
- GAGerhardt Attard
University College London
- FBFrançois‐Clément Bidard
Université Paris-Saclay, Institut Curie, Université de Versailles Saint-Quentin-en-Yvelines
- GCGiuseppe Curigliano
University of Milan, European Institute of Oncology
- LDLeticia De Mattos‐Arruda
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, IrsiCaixa
Topics & keywords
Topics
Keywords
- Medicine
- Circulating tumor DNA
- Oncology
- Cancer
- Precision medicine
- Internal medicine
- Medical physics
- Family medicine
No related works found for this paper.
Funding
- MAMesothelioma Applied Research Foundation
- AAmgen
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GGlaxoSmithKline
- SSanofi
- APAriad Pharmaceuticals
- CCelgene
- MKMerck KGaA
- LLLes Laboratories Pierre Fabre
- RIRoche Innovation Center Zurich
- ESEuropean Society for Medical Oncology
- SServier
- GGenentech
- CPChugai Pharmaceutical
- DSDaiichi Sankyo Europe